Immune-related adverse events with mogamulizumab in cutaneous T-cell lymphoma: A multicentre study.
BACKGROUND Mogamulizumab, an anti-CCR4 monoclonal antibody used in advanced mycosis fungoides (MF) and Sezary syndrome (SS), also depletes regulatory T cells, potentially leading to immune-related adverse events (irAEs). Unlike mogamulizumab-associated rash (MAR), other irAEs remain poorly documented to date. OBJECTI...